GSK shares fall on weaker vaccine sales and restructuring costs despite strong quarter
Drugmaker’s third-quarter results beat expectations but investors focus on Shingrix slump and looming patent cliff
Shares in GSK slid on Wednesday, making it the biggest faller on the FTSE 100, despite the UK drugmaker reporting better-than-expected financial results for the third quarter. Investors were unnerved by weaker vaccine sales, £318m in restructuring charges and the overall outlook, including a looming patent cliff for its blockbuster HIV drug dolutegravir.